Guidelines for the Use of Retrievable and Convertible Vena Cava Filters: Report from the Society of Interventional Radiology Multidisciplinary Consensus Conference

Kaufman, John A.; Kinney, Thomas B.; Streiff, Michael B.; Sing, Ronald F.; Proctor, Mary C.; Becker, Daniel; Cipolle, Mark; Comerota, Anthony J.; Millward, Steven F.; Rogers, Frederick B.; Sacks, David; Venbrux, Anthony C.
February 2007
World Journal of Surgery;Feb2007, Vol. 31 Issue 2, p251
Academic Journal
The article focuses on the guidelines for the use of retrievable and convertible vena cava filters, based from report of the Society of Interventional Radiology Multidisciplinary Consensus Conference. Key information regarding the approved changes to the directions to the use of filters by the U.S. Food and Drug Administration are discussed. Instructions on the clinical application of the nonpermanent vena cava filters are also presented.


Related Articles

  • Use of Emboli-Blocking Filters Increases, But Rigorous Data Are Lacking. Brender, Erin // JAMA: Journal of the American Medical Association;3/1/2006, Vol. 295 Issue 9, p989 

    The article reports on the controversy over permanent and retrievable inferior vena cava (IVC) devices, which are used to trap blood clots before they reach the lungs. There is a long-term risk for complications and patients often have to make a lifelong commitment to anticoagulation therapy...

  • Potency differences in generic thyroid drugs cited.  // Patient Care;Nov2004, Vol. 38 Issue 11, p8 

    Reports on the concerns the American Thyroid Association (ATA) and the American Association of Clinical Endocrinologists (AACE) regarding the approval of generic forms of levothyroxine by the U.S. Food and Drug Administration (FDA), as of November 2004. Overview of bioequivalence studies...

  • Companies warned over hormone therapies.  // Pharmaceutical Technology Europe;Dec2005, Vol. 17 Issue 12, p14 

    The article reports on the action initiated by Food Drug Administration (FDA) and the Federal Trade Commission (FTC) against numerous marketers of unapproved alternative hormone therapies in the U.S. FDA issued warning letters to numerous dietary supplement and hormone cream marketers that have...

  • FDA: THE GUTLESS TIGER. Jacobson, Michael F. // Nutrition Action Health Letter;Jul/Aug2003, Vol. 30 Issue 6, p2 

    Examines the shortcomings of the U.S. Food and Drug Administration (FDA). Factor being blamed for the slowness and inactivity of the FDA.

  • WASHINGTON report. Dickinson, James D // Medical Marketing & Media;Dec2000, Vol. 35 Issue 12, p30 

    Reports on news and developments related to medical policy in the United States as of December 2000. U.S. Food and Drug Administration's warning against the use of prescription and over-the-counter drugs containing phenylpropanolamine; General Pharmaceutical Association's request for the FDA to...

  • Shrunken glands spark sweetener controversy. Coghlan, Andy // New Scientist;11/23/91, Vol. 132 Issue 1796, p13 

    Reports that a consumer group in the United States has expressed doubts about the safety of sucralose, a sweetener which was approved for sale in Canada in September 1991. Center for Science in the Public Interests' (CSPI) call for additional toxological studies to establish whether the...

  • FDA assigns Drug Master File to European cancer group. Steimle, Sabine // JNCI: Journal of the National Cancer Institute;09/16/98, Vol. 90 Issue 18, p1331 

    Reports that the Treatment Division of the European Organization for Research and Treatment of Cancer (EORTC) in Brussels, Belgium received a Drug Master File number from the United States Food and Drug Administration (FDA). Significance of the move by the FDA; What is the assigned Drug Master...

  • FDA Advisory Committees: Their Purpose, How They Work, and How You Can Become a Member. Brady, Charles // American Journal of Gastroenterology;Apr2006, Vol. 101 Issue 4, p689 

    The article provides information about the purpose, operation and membership associated with the advisory committees of the U.S. Food and Drug Administration (FDA). Advisory committees of the FDA offer independent expertise and technical guidance to the development of the safety of the products...

  • The Pulse on Global Trials. Howes, Matthew // CenterWatch Weekly;11/9/2015, Vol. 19 Issue 44, p7 

    The article reports that the U.S. FDA and EMA have developed fast-track review-and-approval processes for novel agents in rare diseases, with advocacy organizations maintaining media pressure on government and businesses to improve care of elderly and undeserved populations.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics